麻豆传媒

McMichael has published numerous articles and book chapters on the subjects of scalp and hair disorders and quality of life issues surrounding disorders of pigmentation. She is listed in Best Doctors in America and is a diplomat of the American Board of Dermatology. McMichael has served on several editorial review boards and is a contributing editor for Cosmetic Dermatology as well as a contributing editor for reviews in The Dermatologist.

Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer, Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.
In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.
Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

Education & Training:
Research Fellow-Dana-Farber Cancer Institute (2002)
Fellow-Harvard Medical School Dermatopathology Training Program (2000)
Chief Resident-Brigham & Women's Hospital (1999)
Resident-Brigham & Women's Hospital (1998)
Research Fellow-University of Wisconsin (1996)
MD-Cornell University Medical College (1994)
PhD-Cornell University Medical College (1993)
BA-Cornell University (1986)

To Kathleen C. Suozzi, MD, the prevention and reversal of sun damage has become a passion. 鈥淚n my dermatology care and research, I see how sun exposure leads to the development of skin cancers and causes the skin to age prematurely,鈥� she says.
Dr. Suozzi specializes in the treatment of skin cancer with a technique called Mohs surgery. The technique is used to remove cancer cells layer by layer, while preserving normal tissue. She received advanced training in dermatologic surgery at Yale School of Medicine. She is widely published in scientific journals and has presented her research about how skin cancer develops at national conferences including the American Academy of Dermatology, the American Society of Dermatologic Surgery, the Society of Investigative Dermatology and the American College of Mohs Surgery. She鈥檚 committed to alerting people about the dangers of sun exposure. 鈥淧eople accumulate sun damage over a lifetime, starting in childhood. I frequently hear from patients that they were not aware of the risks of sun exposure during their youth,鈥� she says. "But it is never too late to start protecting your skin from UV damage."
In addition to treating skin cancers, Dr. Suozzi uses advanced technologies such as photodynamic therapy, laser treatments and medications to help treat UV-induced damage to the skin. "These technologies can help reverse visible signs of aging and address precancerous changes in the skin,鈥� she says.

Education & Training:
Resident-Yale School of Medicine (2016)
Internship-Memorial Sloan-Kettering Cancer Center (2013)
MD-NYU School Of Medicine (2012)
BS-Duke Univeristy, Biology (2005)

Honors & Recognition:
2022 Rising Star Award-Academic Cosmetic Dermatologists (AACD)

Jonathan Leventhal, MD, is the director of the Onco-Dermatology Program at Smilow Cancer Hospital at Yale New Haven. He treats patients undergoing cancer treatment who experience itchy or painful rashes, as well as hair and nail changes that can result from either their disease or treatment, including chemotherapy, immunotherapy, radiation or stem cell transplantation.
鈥淥ne of the most rewarding aspects of my job is improving the quality of life for patients with cancer who are affected by adverse skin events,鈥� he says.
Seeing an onco-dermatologist like Dr. Leventhal can make the difference between a patient being able to continue receiving a cancer treatment or having to be taken off it when the skin conditions become too severe. 鈥淚f left untreated, some skin, hair and nail conditions can become quite debilitating, even disfiguring and may negatively impact health and ability to perform day-to-day activities,鈥� says Dr. Leventhal. He helps to manage these skin problems so that patients with cancer can continue their treatments and enjoy a better quality of life.
In addition to his role at Smilow, Dr. Leventhal, an associate professor of dermatology and associate director of the residency program at Yale School of Medicine, cares for patients with a wide range of skin conditions in Yale Medicine Dermatology鈥檚 New Haven and Branford locations. He performs routine skin cancer screening examinations and also treats general skin problems鈥攆rom acne to psoriasis to eczema. He is also the Associate Residency Program Director and is Principal Investigator of several clinical trials involving the management of cutaneous reactions to cancer therapy.
"Every day I am excited to come to work, treating various skin conditions affecting my patients and helping patients with cancer continue their potentially life-saving treatments,鈥� says Dr. Leventhal. 鈥淪kin diseases can impact the way people see themselves and can affect how people feel, both physically and emotionally. My work is particularly gratifying when I can improve my patients' overall comfort, happiness and health.鈥�

Education & Training:
Resident- Yale University School of Medicine (2016)
Intern- NYU Langone Hospital - Long Island (2013)
MD- New York University (2012)

Honors & Recognition:
2018 Medical Education Fellowship
2015 Hugh L. Dwyer Memorial Fund Award for Clinical Excellence

Professor, Department of Dermatology, School of Medicine
Director, Skin Study Center, School of Medicine

Teaching Interests
Specialties:
Cosmetic, Laser Dermatology, Photomedicine, General Dermatology

Research Information
Research Interests
Dr. Baron鈥檚 research lab main goal is to facilitate translational research in dermatology and photodermatology. This includes development of photodynamic therapy (PDT) and photoprotective strategies, as well as understanding mechanisms of disease and intervention in the context of investigator-initiated human studies.

The current areas of focus include:

Photodynamic therapy with silicon phthalocyanine Pc4 for neoplastic
Inflammatory (psoriasis) and infectious diseases of the skin
Analysis of effects of sunscreens and antioxidants in human skin
Oral probiotics and UV-induced cutaneous immunosuppression
Awards and Honors
Excellent Performance as Chief of Dermatology 2005 Cleveland Veterans Affairs Medical Center
Outstanding Performance as Chief of Dermatology 2008 Cleveland Veterans Affairs Medical Center
Helen Evans Midcareer Faculty Award 2011 School of Medicine
Teledermatology cited as Best Practices 2011 Department of Veterans Affairs
External Appointments
Associate Professor - Dermatology, Case Western Reserve University
Chief - Dermatology, VA Medical Center, Cleveland, Ohio
Director - Photomedicine, Attending Medical Staff, Dermatology, University Hospitals of Cleveland, Ohio
Director - Skin Study Center, University Hospitals Research, Institute/Case Western Reserve University, Cleveland, OH
Clinical Program Director - VISN 10 Teledermatology
Acting Director - Skin Study Center, University Hospitals Research Institute, Cleveland, OH
Director - Dermatology for Primary Care Training, Firm B, Medicine Clinic, VA Medical Center, Cleveland, OH
Publications
View Dr. Baron's publications in PubMed

View Dr. Baron's PubMed by Topic:
PDT, Photoprotection, Phototherapy, Photopheresis

Book Chapters:

Taylor CR and Baron ED. Guttate Psoriasis. In: William James (Chief Ed.) eMedicine: Dermatology. St. Petersburg: eMedicine Corporation, 2000.
Taylor CR and Baron ED. Pustular Psoriasis. In: William James (Chief Ed.) eMedicine: Dermatology. St. Petersburg: eMedicine Corporation, 2000.
Baron ED and Taylor CR. Solar Urticaria. In: William James (Chief Ed.) eMedicine: Dermatology. St. Petersburg: eMedicine Corporation, 2000.
Baron ED. The immune system and carcinogenesis of basal and squamous cell carcinomas. In: Jorge Reichrath (Chief Ed) Molecular mechanisms of basal and squamous cell carcinoma. 2006. Landes Bioscience/Springer, USA; pp 43-48.
Yu SH, Bordeaux JS, Baron ED. The immune system and skin cancer. In: Reichrath J, ed. Sunlight, Vitamin D and Skin Cancer, Second Edition. Austin/NewYork: Landes Bioscience and Springer Science+Business Media, 2013; epub ahead of print http://www.landesbioscience.com/curie/chapter/5403/.
Books

Elma D. Baron, ed. Light-based therapies for skin of color. Springer Verlag publishers, London, 2009.
Education
MD University of the Philippines College of Medicine, Manila, Philippines
Residencies, Internships and Fellowships
Dermatology Residency Philippine General Hospital/University of the Philippines, Manila
Clinical Fellowship in Photomedicine Department of Dermatology, Massachusetts General Hospital/Harvard Medical School, Boston, MA
Research Fellowship in Photoimmunology Skin Study Center, Department of Dermatology, University Hospitals of Cleveland Research Institute/Case Western Reserve University, Cleveland, OH
Clinical Fellowship in Dermatology and Photobiology Department of Dermatology, University Hospitals of Cleveland, Cleveland, OH
Internship in Internal Medicine Department of Internal Medicine, University Hospitals of Cleveland, Cleveland, OH
Trainee: Certificate Course in The Advancing Manager Case Western Reserve University Weatherhead School of Management, Cleveland, OH
Additional Information
Elma Baron, M.D. joined Case Western Reserve University and University Hospitals Cleveland Medical Center in 2003. Dr. Baron鈥檚 training, began at the University of the Philippines, College of Medicine, where she was accepted into the Dermatology Residency and became Chief Resident. She then entered fellowships in Clinical Photomedicine at Massachusetts General Hospital/Harvard Medical School followed by a fellowship in Dermatology, Photobiology, Translational and Cutaneous Oncology at Case Western Reserve University/University Hospitals Cleveland Medical Center/VA Medical Center, and a research fellowship in Lasers & Photomedicine.

Dr. Baron is the Chief of the Dermatology Service at the VA Medical Center, Director of Photomedicine, at University Hospitals Cleveland Medical Center, and Director of Translational Research Core & Skin Study Center, at University Hospitals Cleveland Medical Center. As Chief of the Dermatology Service at the VA Medical Center, Dr. Baron pioneered Telemedicine to accommodate the needs of 13 Community Based Outpatient Centers serving a large region of Ohio veterans. As Director of Photomedicine, Dr. Baron is highly recognized for her expertise in diseases caused by light exposure, as well as for her expertise in therapeutics using various wavelengths of light for specific conditions. As Director of the Skin Study Center, Dr. Baron oversees a clinical research unit in which she has developed the capability to measure a suite of human skin physiologic and damage responses to quantifiable environmental stressors and injuries. As Director of Translational Research Core she interfaces with numerous investigators who wish to translate basic findings into studies using elicited responses normal human skin, or skin from patients with certain skin diseases or malignancies. Dr. Baron is highly committed to enabling research fellows and students to have a positive productive research experience to further their career development. She is heavily engaged in all aspects of our teaching mission. Her teaching is highly valued by the residents, who learn their basic surgical skills, medical dermatology, and phototherapeutic skills, including laser therapies, from Dr. Baron.

Dr. Baron鈥檚 academic area of focus is in Photomedicine, Translational Medicine, and Teledermatology. She is nationally recognized for her contributions to understanding how sunlight and specific wavelengths of light interact with skin and modify its structure and function in health, disease and premature aging.

Clinical Expertise: Dr. Girardi is Co-Director of the Yale Cutaneous Lymphoma Group, Director of the Photopheresis Unit, and Director of the Phototherapy Unit at the Yale Comprehensive Cancer Center and Yale-New Haven Hospital. Dr. Girardi is also an active member of the national and international organizations (United States Cutaneous Lymphoma Consortium, International Society of Cutaneous Lymphoma) that formulate and publish the criteria guidelines for the diagnosis and treatment CTCL, and is executing the largest clinical database for CTCL. He has published over 150 scientific manuscripts, clinical reports, and book chapters, including on the genetic basis of CTCL and a Medical Progress Report for the New England Journal of Medicine. Dr. Girardi was awarded the 2023 Yale Blavatnik Innovation Award for the development of new treatments for T cell lymphoma and the 2017 Zeligman Award by Johns Hopkins University for his expertise in understanding the genetic and immunologic mechanisms that cause CTCL, and he has delivered over 100 national and international lectures including at the National Institutes of Health, U.S. Food and Drug Administration, Harvard University, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Kings College London, and Northwestern University. Dr. Girardi is currently Professor, Vice Chair, and NIH T32 Research Fellowship Co-Director for the Department of Dermatology, Yale School of Medicine.
Disease Interests: the diagnosis and management of cutaneous lymphoma and related conditions, including: mycosis fungoides (MF) cutaneous T cell lymphoma (CTCL) [variants of which include folliculotropic MF, follicular mucinosis MF, hypopigmented (hypomelanotic) MF, pagetoid reticulosis (Woringer-Kolopp disease), erythrodermic MF, tumor-stage (T3) MF, transformed MF (T-MF), large cell transformation MF (LCT-MF), and Sézary syndrome (SS)]; CD30+ lymphoproliferative disorders (CD30+ LPD) including lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL); CD4+ small/medium/pleomorphic T cell lymphoma (CD4+ SMPTCL); cutaneous B cell lymphoma (CBCL) [variants of which include primary cutaneous marginal zone B cell lymphoma (PCMZBCL) and primary cutaneous follicle center B cell lymphoma (PCFLBCL); lymphocytoma cutis (pseudolymphoma); parapsorias (including large plaque and small plaque variants); subcutaneous panniculitic T cell lymphoma (SCPTCL); cutaneous CD8+ cytotoxic T cell lymphoma; cutaneous gamma-delta T cell lymphoma; and cutaneous NK/T cell lymphoma. Laboratory Research: During more than 20 years leading an NCI-funded research program at Yale, Dr. Girardi’s laboratory is credited with major contributions to our understanding of skin biology immunology and skin cancer development, including the elucidation of roles for gamma-delta T cells, NKG2D ligands, Langerhans cells, and innate lymphoid cells. Dr. Girardi has served as the Co-Director for the Yale Comprehensive Cancer Center’s Immunology and Immunotherapy Program, and is the holder/filer of 10+ biomedical patents on cancer diagnosis and treatment and co-founder of two Yale startup companies: Stradefy Biosciences and Devana Bio. Dr. Girardi's work has been published in Science(x2), J Exp Med (x3), Nature, Nature Immunology (x4), Nature Genetics (x2), Nature Materials, PNAS (x4), and Blood (x4) – with a Google Scholar Profile of h-index 45+, i10-index 100+, 10,000+ citations. 
Dr. Girardi’s current research programs include:

The role of local immune cells in the development of cutaneous carcinogenesis. Using state-of-the-art genetically engineered mice, immunobiology techniques, and confocal imaging, the Girardi laboratory is dissecting how various immune cells, resident within and recruited to the skin, contribute the skin cancer development.
Novel approaches to the diagnosis and treatment of cutaneous T cell lymphoma (CTCL). Overseeing one of the largest centers for CTCL, Dr. Girardi and colleagues use genetic sequencing and robotic transfer to enhance diagnosis and to screen and develop new pharmaceutical agents in the treatment of this malignancy, and is engineer new small molecules and immunotherapeutics for T cell
Biodegradable nanotechnology in the prevention and treatment of skin cancer. In collaboration with W.M. Saltzman (Professor, Yale Biomedical Engineering) and Douglas Brash (Professor, Genetics), Dr. Girardi’s lab is developing novel strategies for skin cancer prevention and treatment.

Academic Director, Mohs and Dermatologic Surgery CenterDirector, High-Risk Skin Cancer Clinic, Dana-Farber Brigham Cancer Center Director, Micrographic Surgery and Dermatologic Oncology Fellowship Program
Associate Professor of Dermatology, Harvard Medical School







Leadership Title

Academic Director, Mohs and Dermatologic Surgery Center
Director, High-Risk Skin Cancer Clinic, Dana-Farber Brigham Cancer Center
Program Director, Micrographic Surgery and Dermatologic Oncology Fellowship Program


 

Specialties
Dermatology



Clinical Interests

Basal Cell Carcinoma
Cutaneous Oncology (Skin Cancer)
Dermatologic Oncology
Melanoma
Mohs Surgery
Non-Melanoma Skin Cancer
Public Health
Squamous Cell Carcinoma











 
Education





Internship
New York University Langone Medical Center, 2010 - 2011

 

Medical School
New York University School of Medicine, 2006 - 2010

 

Residency
Albert Einstein College of Medicine, 2011 - 2014



Board Certifications
Dermatology, 2014
Micrographic Dermatologic Surgery, 2021